Cargando…

Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease

Detalles Bibliográficos
Autores principales:	Kang, Eun Ae, Cheon, Jae Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289836/ https://www.ncbi.nlm.nih.gov/pubmed/35843685 http://dx.doi.org/10.5009/gnl220186

Ejemplares similares

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
por: Kim, Su Young, et al.
Publicado: (2020)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
por: Lee, Ji Min, et al.
Publicado: (2022)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents
por: Guidi, Luisa, et al.
Publicado: (2013)

Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
por: Kim, Ju Young, et al.
Publicado: (2021)

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity
por: Lee, Ko Eun, et al.
Publicado: (2019)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Microbial Modulation in Inflammatory Bowel Diseases
por: Yu, Jongwook, et al.
Publicado: (2022)

Hyperactive neutrophil chemotaxis contributes to anti‐tumor necrosis factor‐α treatment resistance in inflammatory bowel disease
por: Yau, Tung On, et al.
Publicado: (2022)

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
por: Park, Jihye, et al.
Publicado: (2018)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
por: Gareb, Bahez, et al.
Publicado: (2020)

The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Blockers
por: Byun, Ja Min, et al.
Publicado: (2015)

Incidence and Prevalence of Inflammatory Bowel Disease across Asia
por: Park, Jihye, et al.
Publicado: (2021)

Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
por: Park, Yong Eun, et al.
Publicado: (2022)

Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
por: Han, So Jung, et al.
Publicado: (2023)

Association of tumor necrosis factor-α and -β gene polymorphisms in inflammatory bowel disease
por: Al-Meghaiseeb, Ebtissam Saleh, et al.
Publicado: (2016)

Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents
por: Estefan, Sergio, et al.
Publicado: (2021)

Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management
por: Park, Jihye, et al.
Publicado: (2021)

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
por: Schultheiss, Johannes P. D., et al.
Publicado: (2021)

The gut fungal and bacterial microbiota in pediatric patients with inflammatory bowel disease introduced to treatment with anti-tumor necrosis factor-α
por: Ventin-Holmberg, Rebecka, et al.
Publicado: (2022)

Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
por: Kim, Duk Hwan, et al.
Publicado: (2017)

Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases
por: Kim, Jung Min, et al.
Publicado: (2020)

Bilateral Acute Retinal Necrosis Treated With Antivirals and Corticosteroids
por: Ramirez Marquez, Estefania, et al.
Publicado: (2023)

Advances in the Endoscopic Assessment of Inflammatory Bowel Diseases: Cooperation between Endoscopic and Pathologic Evaluations
por: Cheon, Jae Hee
Publicado: (2015)

The Effect of the Menstrual Cycle on Inflammatory Bowel Disease: A Prospective Study
por: Lim, Sun Min, et al.
Publicado: (2013)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor
por: Pagnini, Cristiano, et al.
Publicado: (2019)

Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)

Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents
por: Ghweil, Ali A, et al.
Publicado: (2019)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

New Antiviral Agents for Hepatitis C
por: Pawlotsky, Jean-Michel
Publicado: (2012)

Antiviral Immunity and Prophylaxis
Publicado: (2011)

Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study
por: Song, Joo Hye, et al.
Publicado: (2021)

Hepatitis B sero-prevalence among hematology patients: importance of Anti-HbcAb and efficiency of antiviral prophylaxis
por: Kantar, Funda Ugur, et al.
Publicado: (2022)

Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease
por: Patel, Samir H., et al.
Publicado: (2012)

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
por: Lee, Way-Seah, et al.
Publicado: (2017)

Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
por: Cohen-Mekelburg, Shirley, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kej7ne9hai5lmejquu70in69m1